May 8
Current report
8-K
Financial results
CLSDQ · Clearside Biomedical, Inc. · Documents
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued. Based on our current plans and forecasted expenses and our cash and cash equivalents, we do not believe we will be able to fund our operations for the next 12 months from the date of this filing.”View the 10-Q filed Nov 14, 2025
Market Cap
$1.30M
Shares
5.23M
Volume
—
Avg daily vol (3M)
—
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2020
May 8
Quarterly report
10-Q
FY2020 Q1, ended Mar 31
Quarterly report for FY2020 Q1
Revenue $4.1M
▲ 9004.4%
Net loss $2.91M
May 8
Registration statement
S-3
Registration statement
Apr 29
Proxy statement
DEF 14A
Meeting Jun 18, 2020
Proxy statement
Apr 29
Proxy statement
DEFA14A
Proxy statement
Apr 28
Current report
8-K
Events of Apr 27
Entered into a material agreement, Financial results, Regulation FD disclosure, Other events
Apr 22
Current report
8-K
Events of Apr 21
Director or officer change, or executive pay, Regulation FD disclosure
Apr 8
Current report
8-K
Other events
Mar 16
Current report
8-K
Events of Mar 11
Director or officer change, or executive pay
Mar 13
Current report
8-K
Events of Mar 10
Entered into a material agreement
Mar 13
Annual report
10-K
FY2019, ended Dec 31
Annual report for FY2019
Revenue $2.17M
▲ 7143.3%
Net loss $30.77M
Mar 11
Current report
8-K
Financial results
Jan 10
Registration statement
S-3
Registration statement
Jan 3
Current report
8-K
Events of Dec 30
Director or officer change, or executive pay
Showing 101–114 of 114 documents